|
AstraZeneca PLC on Saturday celebrated phase 3 trial results on baxdrostat, an aldosterone synthase inhibitor that targets one of the hormones driving elevated blood pressure and increased cardiovascular and renal risk. The Cambridge, England-based pharmaceutical company said baxdrostat showed a significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension at 12 weeks when compared to a placebo. AstraZeneca added that the safety profile of baxdrostat was consistent with its mechanism of action with most adverse events being mild. Sharon Barr, executive vice president, BioPharmaceuticals research & development at AstraZeneca, said: ‘The BaxHTN phase III results demonstrate baxdrostat’s potential in tackling one of the toughest challenges in cardiovascular care, which is hypertension that is hard to control despite multiple therapies. ‘We look forward to advancing our regulatory filings for baxdrostat with health authorities in the months ahead, in addition to rapidly progressing a robust clinical development programme across indications where aldosterone plays a key role, including chronic kidney disease and heart failure prevention.’ AstraZeneca shares had closed 0.2% lower at 11,790.00 pence each on Friday in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
